Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis - Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction

被引:370
作者
Joosten, LAB
Lubberts, E
Durez, P
Helsen, MMA
Jacobs, MJM
Goldman, M
vandenBerg, WB
机构
[1] UNIV NIJMEGEN HOSP,DEPT RHEUMATOL,NL-6500 HB NIJMEGEN,NETHERLANDS
[2] FREE UNIV BRUSSELS,HOSP ERASMUS,B-1070 BRUSSELS,BELGIUM
来源
ARTHRITIS AND RHEUMATISM | 1997年 / 40卷 / 02期
关键词
D O I
10.1002/art.1780400209
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To examine the role of endogenous interleukin-4 (IL-4) and interleukin-10 (IL-10) and the therapeutic effect of the addition of IL-4 and IL-10 in early and established murine collagen-induced arthritis (CIA). Methods. Murine recombinant IL-4, IL-10, or the combination was given intraperitoneally twice daily from the day of arthritis onset up to 7-10 days of CIA in DBA/1 mice. Anti-IL-4, anti-IL-10, or both antibodies were given intraperitoneally before or after the onset of CIA. The effect of cytokine or anticytokine treatment was monitored visually by macroscopic scoring. Histology and reverse transcription-polymerase chain reaction (RT-PCR) analyses were performed at the end of the treatment period. Results. IL-4 alone did not provoke any effect, IL-10 slightly suppressed the arthritis, but a more pronounced amelioration was found with the combination. This cooperative effect was noted after early treatment but also occurred when the start of treatment was delayed until 1 week after onset. Apart from suppression of macroscopic signs of inflammation, combined treatment with IL-4/IL-10 also reduced cellular infiltrates in the synovial tissue and caused pronounced protection against cartilage destruction. Moreover, levels of mRNA for tumor necrosis factor alpha (TNF alpha) and IL-1 were highly suppressed both in the synovial tissue and in the articular cartilage. In contrast, levels of IL-1 receptor antagonist (IL-1Ra) mRNA remained elevated, which suggests that the mechanism of protection may be related to suppressed production of TNF alpha and IL-1, with concomitant up-regulation of the IL-1Ra/IL-1 balance. However, accelerated onset of CIA and increased severity could be achieved with neutralizing anti-IL-10 antibodies. This expression could be further optimized with a combination of anti-IL-4 and anti-IL-10 antibodies, although anti-IL-4 alone was without effect. Conclusion. Our data are consistent with a dominant role of IL-10 in the natural suppression of arthritis expression, whereas combined treatment with IL-4 and IL-10 appears of potential therapeutic value, not only at the onset, but also in established arthritis.
引用
收藏
页码:249 / 260
页数:12
相关论文
共 58 条
[21]   2 TYPES OF MOUSE T-HELPER CELL .4. TH2 CLONES SECRETE A FACTOR THAT INHIBITS CYTOKINE PRODUCTION BY TH1 CLONES [J].
FIORENTINO, DF ;
BOND, MW ;
MOSMANN, TR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (06) :2081-2095
[22]  
FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
[23]   INTERLEUKIN-10 REDUCES THE RELEASE OF TUMOR-NECROSIS-FACTOR AND PREVENTS LETHALITY IN EXPERIMENTAL ENDOTOXEMIA [J].
GERARD, C ;
BRUYNS, C ;
MARCHANT, A ;
ABRAMOWICZ, D ;
VANDENABEELE, P ;
DELVAUX, A ;
FIERS, W ;
GOLDMAN, M ;
VELU, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) :547-550
[24]  
HART PH, 1995, IMMUNOLOGY, V84, P536
[25]   POTENTIAL ANTIINFLAMMATORY EFFECTS OF INTERLEUKIN-4 - SUPPRESSION OF HUMAN MONOCYTE TUMOR NECROSIS FACTOR-ALPHA, INTERLEUKIN-1, AND PROSTAGLANDIN-E2 [J].
HART, PH ;
VITTI, GF ;
BURGESS, DR ;
WHITTY, GA ;
PICCOLI, DS ;
HAMILTON, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (10) :3803-3807
[26]  
HULI J, 1989, J IMMUNOL, V142, P800
[27]   CONTINUOUS ADMINISTRATION OF ANTI-INTERLEUKIN-10 ANTIBODIES DELAYS ONSET OF AUTOIMMUNITY IN NZB/W F1-MICE [J].
ISHIDA, H ;
MUCHAMUEL, T ;
SAKAGUCHI, S ;
ANDRADE, S ;
MENON, S ;
HOWARD, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (01) :305-310
[28]  
JACOBS MJM, 1994, IMMUNOLOGY, V83, P390
[29]  
JENKINS JK, 1994, LYMPHOKINE CYTOK RES, V13, P47
[30]  
JOOSTEN LAB, 1994, CLIN EXP IMMUNOL, V97, P204